|
1
|
Gharehbaghi K, Zhen W, Fritzer-Szekeres M,
Szekeres T and Jayaram HN: Studies on the antitumour activity and
biochemical actions of cyclopentenyl cytosine against human colon
carcinoma HT-29 in vitro and in vivo. Life Sci. 64:103–112. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gharehbaghi K, Szekeres T, Yalowitz JA,
Fritzer-Szekeres M, Pommier YG and Jayaram HN: Sensitizing human
colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine,
in vitro and in vivo. Life Sci. 68:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Bree C, Rodermond HM, Leen R, Medema J
and van Kuilenburg AB: Cyclopentenylcytosine increases gemcitabine
radiosensitisation in human pancreatic cancer cells. Br J Cancer.
98:1226–1233. 2008.PubMed/NCBI
|
|
4
|
Van Bree C, Barten-van Rijbroek AD, Leen
R, Rodermond HM, van Kuilenburg AB and Kal HB: Cyclopentenyl
cytosine has biological and anti-tumour activity, but does not
enhance the efficacy of gemcitabine and radiation in two animal
tumour models. Int J Oncol. 34:813–819. 2009.PubMed/NCBI
|
|
5
|
Kang GJ, Cooney DA, Moyer JD, Kelley JA,
Kim HY, Marquez VE and Johns DG: Cyclopentenylcytosine
triphosphate. Formation and inhibition of CTP synthetase. J Biol
Chem. 264:713–718. 1989.PubMed/NCBI
|
|
6
|
Bierau J, van Gennip AH, Leen R, Meinsma
R, Caron HN and van Kuilenburg AB: Cyclopentenyl cytosine-induced
activation of deoxycytidine kinase increases gemcitabine anabolism
and cytotoxicity in neuroblastoma. Cancer Chemother Pharmacol.
57:105–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crul M, van Waardenburg RC, Beijnen JH and
Schellens JH: DNA-based drug interactions of cisplatin. Cancer
Treat Rev. 28:291–303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Myint WK, Ng C and Raaphorst GP: Examining
the non-homologous repair process following cisplatin and radiation
treatments. Int J Radiat Biol. 78:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawrence TS, Blackstock AW and McGinn C:
The mechanism of action of radiosensitization of conventional
chemotherapeutic agents. Sem Radiat Oncol. 13:13–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergs JW, Haveman J, ten Cate R, Medema
JP, Franken NA and van Bree C: Effect of 41ºC and 43ºC on cisplatin
radiosensitization in two human carcinoma cell lines with different
sensitivities for cisplatin. Oncol Rep. 18:219–226. 2007.
|
|
12
|
Haveman J, Castro Kreder N, Rodermond HM,
van Bree C, Franken NA, Stalpers LJ, Zdzienicka MZ and Peters GJ:
Cellular response of X-ray sensitive hamster mutant cell lines to
gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep. 12:187–192.
2004.PubMed/NCBI
|
|
13
|
Van Bree C, Castro Kreder N, Loves WJ,
Franken NA, Peters GJ and Haveman J: Sensitivity to ionizing
radiation and chemotherapeutic agents in gemcitabine-resistant
human tumour cell lines. Int J Radiat Oncol Biol Phys. 54:237–244.
2002.PubMed/NCBI
|
|
14
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barendsen GW, van Bree C and Franken NA:
Importance of cell proliferative state and potentially lethal
damage repair on radiation effectiveness: Implications for combined
tumour treatments (review). Int J Oncol. 19:247–256. 2001.
|
|
16
|
Barendsen GW: Parameters of
linear-quadratic radiation dose-effect relationships: dependence on
LET and mechanisms of reproductive cell death. Int J Radiat Biol.
71:649–655. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franken NA, van Bree C, Veltmaat MA,
Rodermond HM, Haveman J and Barendsen GW: Radiosensitization by
bromodeoxyuridine and hyperthermia: analysis of linear and
quadratic parameters of radiation survival curves of two human
tumour cell lines. J Radiat Res. 42:179–190. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franken NA, van Bree C, Kipp JBA and
Barendsen GW: Modification of potentially lethal damage in
irradiated Chinese hamster V79 cells after incorporation of
halogenated pyrimidines. Int J Radiat Biol. 72:101–109. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Franken NA, van Bree C, Streefkerk JO,
Kuper IMJA, Rodermond HM, Kipp JBA, Haveman J and Barendsen GW:
Radiosensitization by iodo-deoxyuridine in cultured SW-1573 human
lung tumour cells: Effects on α and β of the linear-quadratic
model. Oncol Rep. 4:1073–1076. 1997.PubMed/NCBI
|
|
20
|
Akudugu JM and Slabbert JP: Modulation of
radiosensitivity in Chinese hamster lung fibroblasts by cisplatin.
Can J Physiol Pharmacol. 86:257–263. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bergs JW, Franken NA, ten Cate R, van Bree
C and Haveman J: Effects of cisplatin and gamma-irradiation on cell
survival, the induction of chromosomal aberrations and apoptosis in
SW-1573 cells. Mutat Res. 594:148–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilkins DE, Heller DP and Raaphorst GP:
Inhibition of potentially lethal damage recovery by cisplatin in a
brain tumour cell line. Anticancer Res. 13:2137–2142.
1993.PubMed/NCBI
|
|
23
|
Begg AC, van Der Kolk PJ, Dewit L and
Bartelink H: Radiosensitization by cisplatin of RIF1 tumour cells
in vitro. Int J Radiat Biol. 50:871–884. 1986. View Article : Google Scholar : PubMed/NCBI
|
